Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule

Peter S. Linsley, Philip M. Wallace, Jennifer Johnson, +5

Science

Autoimmune DiseaseAllergySoluble FormB7 MoleculeMedicine +12

New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

Philip E. Thorpe, Philip M. Wallace, Phillip P. Knowles, +6

PubMed

ImmunotoxicologyDisulfide LinkageImproved StabilityImmunologyHindered Disulfide Bond +18

Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

P E Thorpe, Philip M. Wallace, P.P. Knowles, +5

PubMed

Deglycosylated Ricin A-chainSmpt Cross-linkerImmunotoxicologyImmunologyMonoclonal Anti-thy-1.1 Antibody +16

Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.

Maria‐Ana Ghetie, Richard May, Mark Till, +7

PubMed

ImmunologyImmunoeditingPathologyImmunologic MechanismHd37 Antibodies +20

CTLA4Ig TREATMENT AMELIORATES THE LETHALITY OF MURINE GRAFT-VERSUS-HOST DISEASE ACROSS MAJOR HISTOCOMPATIBILITY COMPLEX BARRIERS

Philip M. Wallace, Jennifer Johnson, John F. MacMaster, +3

Transplantation

HistocompatibilityTransplant RejectionCell TherapyTransplantationAutoimmune Disease +13

Regulation of Inflammatory Responses by Oncostatin M

Philip M. Wallace, John F. MacMaster, Katherine A. Rouleau, +4

The Journal of Immunology

ImmunologyImmune RegulationInnate ImmunityImmune SystemInflammatory Arthritis +20

Regulation of an extrathymic T-cell development pathway by oncostatin M

Christopher H. Clegg, Jeffrey T. Rulffes, Philip M. Wallace, +1

Nature

Oncostatin MSignal TransductionAutoimmune DiseaseLymphocyte DevelopmentImmune Cell Development +10

Characterization of Monoclonal Antibodies That Recognize Canine CD34

Peter A. McSweeney, Katherine A. Rouleau, Philip M. Wallace, +7

Blood

Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.

Philip M. Wallace, John F. MacMaster, Virginia F. Smith, +3

PubMed

Cytosine DeaminaseImmunologyPathologyImmunotherapyTumor Biology +14

Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment.

Philip M. Wallace, Jacob Rodgers, Gina Leytze, +2

The Journal of Immunology

Clinical ImmunologyT-regulatory CellImmunologyAntigen ProcessingCd4 T Cell Responses +15